Archive
Proactive news headlines: Clipper Logistics, AfriTin Mining, Faron Pharma, Union Jack Oil, Eckoh ...
A glance at some of the day's highlights from the Proactive Investors newswire
Company
Faron Pharmaceuticals Limited
LON:FARN
Faron Pharmaceuticals is a global, clinical-stage biopharmaceutical company, focused on creating innovative cancer treatments that leverage the patient’s own immune system. The company’s lead asset bexmarilimab is currently being investigated in Phase I/II clinical trial as a potential therapy for patients with hematological cancers in combination with other standard treatments.
418 stories · page 10 of 21
Faron Pharma updates on progress of Clevegen and Traumakine ahead of R&D day
The biopharma firm said Trumakine will now be subject to a third trial to investigate whether the company’s IV IFN beta-1a can treat coronavirus
Faron Pharma plans to initiate new state of the art process for manufacture of interferon (IFN) beta-1a
To support this, Faron said, it has received a €2,100,000 low interest rate loan from Business Finland, the governmental innovation financing agency of Finland.
Faron Pharma receives €2.5mln to accelerate cancer clinical trial
The award has come from the European Innovation Council Accelerator pilot scheme, which exists to support small companies and scientists working on breakthrough products
Faron Pharma shares trial data at ASCO; updates on cancer trial recruitment
The poster presentation will show Faron’s precision cancer immunotherapy Clevegen was well-tolerated without ‘dose-limiting toxicities'
Faron Pharmaceuticals chief hails as crucial new data that help explain unexpected phase III result
Dr Markku Jalkanen applauded the "scientific detective work" carried out during the analysis of glucocorticoids
Faron Pharmaceuticals jumps as it secures grant from Business Finland
Faron said the €800,000 grant will enable characterisation of immunological responses in its MATINS trial, which is currently investigating the tolerability, safety and efficacy of its Clevegen precision cancer immunotherapy
Archive
Small Cap Wrap - FARON Pharma; Kingswood Holdings;Gaming Realms;
FARON Pharma 370p £173m (AIM:FARN) A global contract development and manufacturing organisation AGC Biologics has been selected to be the commercial scale manufacturer of Clevegen, Faron's wholly-owned novel precision cancer immunotherapy t
Faron Pharma selects manufacturing partner for cancer immunotherapy drug candidate
AGC Biologics will help support the expansion of trials of Clevegen
Faron Pharmaceuticals confident on the potential of both its coronavirus and cancer candidates
The phase I/II MATINS study for Clevegen has recently been expanded.
Faron Pharma donates drug for landmark World Health Organisation coronavirus trial
The group is supplying experimental treatment Traumakine to 2,000 patients
Archive
Small Cap Wrap - NQ Minerals; Faron Pharma and more...
Faron Pharma 355p £154m (AIM:FARN.) Result of placing and issue price. Subject to all conditions being met, the aggregate gross proceeds of the Placing will be up to EUR14 million (£12.18 million) before expenses at EUR4. A discount of 7.6
Faron Pharma raises quick-fire £12.8mln to fund development of two key drug candidates
Faron chief executive, Dr Markku Jalkanen, said the injection of cash would help the company build on the progress of the last year as well as “bring significant value for shareholders during the next 8-12 months
Faron Pharmaceuticals drug accepted to global pneumonia programme
The study will include patients suffering from coronavirus (COVID-19)
Faron Pharma receives green light to broaden MATINS cancer study
An assessment of 30 patients looking into the drug’s tolerability, safety and efficacy found that all bar those receiving the lowest levels of the treatment were subject to dose-related immune activation
Archive
Small Cap Wrap - DRI Healthcare, Faron Pharma, Tracsis and more...
Dish of the day No Joiners Today Off the menu No Leavers Today What’s cooking in the IPO kitchen?
Faron Pharmaceuticals says Clevegen partnership discussions continue
An update was provided in Faron’s 2019 results statement
Proactive news snapshot: Open Orphan, Faron Pharmaceuticals, Greatland Gold...
A look at some of the top stories from the Proactive newswire on Monday
Faron Pharma gets US regulatory green light for late-stage trial
The study set-up reflects feedback from the Food & Drug Administration
Faron Pharmaceuticals study sees second partial response to cancer drug
In Part I of the MATINS trial it was discovered the lung metastasis of a melanoma patient shrank by 44% after receiving the Faron drug